Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Jan 05, 2005	KOLINSKI STUART VP, Gen Counsel & Secretary Trans History: 117	VP, Gen Counsel & Secretary	Form 4	Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)	24,854	--	--
Jul 03, 2014	Sanofi Ten Percent Owner Trans History: 555	Ten Percent Owner	Form 4	Open market or private purchase of non-derivative or derivative security	24,877	$310.21	20,936,871
Nov 17, 2014	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Bona fide gift	24,900	--	369,093
Feb 05, 2014	Sanofi Ten Percent Owner Trans History: 555	Ten Percent Owner	Form 4	Open market or private purchase of non-derivative or derivative security	24,995	$282.85	16,479,755
Mar 23, 2023	VAGELOS P ROY Director Trans History: 742	Director	Form 4	Bona fide gift	25,000	--	312,578
Aug 09, 2021	Van Plew Daniel P EVP & General Mgr, Industrial Trans History: 359	EVP & General Mgr, Industrial	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	25,000	$270.43	51,931
Aug 09, 2021	Van Plew Daniel P EVP & General Mgr, Industrial Trans History: 359	EVP & General Mgr, Industrial	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	25,000	--	25,000
Dec 09, 2020	McCourt Marion SVP Commercial Trans History: 141	SVP Commercial	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	25,000	--	25,000
Dec 09, 2020	MURPHY ANDREW J EVP Research Trans History: 222	EVP Research	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	25,000	--	25,000
Aug 28, 2020	POON CHRISTINE A Director Trans History: 60	Director	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	25,000	$25.45	41,433

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media